2004 Competition Leads 
European Pharmaceutical Review
JUNE 24, 2022
This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused Maarten has significant competition law experience in a variety of sectors. About the author. References.
European Pharmaceutical Review
JULY 4, 2024
4,6 Traditional Herbal Registration The Traditional Herbal Medicines Directive (Directive 2004/24/EC) is implemented in the UK by the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 and came into force on 30 April 2011. 13 Currently, over 350 herbal remedies have been granted a THR licence. 2012/1916).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 27, 2023
If achieved, this would boost the UK’s competitiveness as a leading international site for trials. Mansfield also listed the main elements of The Future Clinical Trials Bill.
PM360
SEPTEMBER 28, 2022
At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Look, competition is healthy.
PM360
JUNE 29, 2022
However, patient uptake hasn’t matched rising market competition. Among surveyed patients, nearly half (47%) couldn’t remember a single preventive migraine brand name, and the leading brand patients did recall— Topamax —is an older drug that was approved for migraine in 2004. What Marketers Can Do.
European Pharmaceutical Review
AUGUST 23, 2022
Article 15 proved that transparent and effective assessments of new technologies were crucial to ensure fair competition between stakeholders that operate in the EU. In addition, he was Head of the Legal Service at the European Medicines Agency from 2004 to 2012. effectiveness and therapeutic efficacy.
European Pharmaceutical Review
DECEMBER 19, 2022
1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.
Expert insights. Personalized for you.
105 
Let's personalize your content